Drug intelligence / Profile preview

TLP-04

Development stage: Preclinical
Lead developer: Telara Pharma
Modality: Small Molecules

Overview

TLP-04 is a small molecule dehydropeptidase-I (DHP-I) inhibitor being developed by Telara Pharma. It is a repurposed formulation of cilastatin, an agent traditionally used to prevent the renal metabolism of the carbapenem antibiotic imipenem. Telara Pharma is developing TLP-04 for an undisclosed indication, leveraging cilastatin's potential nephroprotective and neuroprotective properties. The drug works by inhibiting the DHP-I enzyme (also known as Dipeptidase 1 or DPEP1) located in the brush border of the proximal tubule in the kidney and potentially in the central nervous system, thereby mitigating cellular damage and inflammation. As of early 2024, TLP-04 is in the preclinical stage of development.

Other names: cilastatin

Targets

DPEP1 (Dehydropeptidase 1)

Beyond the preview

Go deeper on TLP-04.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TLP-04.

Explore the full profile